SCHEMBL18740168

SCHEMBL18740168

COC(=O)c1c(C(F)(F)F)nn2c1N(Cc1ccc(C(F)(F)F)cc1)CCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.41
▸ LMNA P02545 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ HIF1A Q16665 2/20 0.38
▸ EPAS1 Q99814 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ PRKAB2 O43741 2/20 0.37
▸ PRKAG1 P54619 2/20 0.37
▸ PRKAA2 P54646 2/20 0.37
▸ PRKAA1 Q13131 2/20 0.37
▸ PRKAG3 Q9UGI9 2/20 0.37
▸ PRKAG2 Q9UGJ0 2/20 0.37
▸ PRKAB1 Q9Y478 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18739965 0.94 MEN1 (0.44) KDM4EPKMMEN1KMT2AALDH1A1
SCHEMBL18740296 0.92 MEN1 (0.39) LMNAMEN1KMT2AALDH1A1POLB
SCHEMBL18758706 0.89 ALDH1A1 (0.42) KDM4ELMNAPKMMEN1KMT2A
SCHEMBL18740303 0.87 KDM4E (0.40) KDM4ELMNAALDH1A1HDAC1HIF1A
SCHEMBL18758571 0.86 PKM (0.41) LMNAPKMMEN1KMT2ASMN1; SMN2
SCHEMBL18740240 0.86 MEN1 (0.45) KDM4EPKMMEN1KMT2AALDH1A1
SCHEMBL18740218 0.85 MEN1 (0.44) LMNAPKMMEN1KMT2AALDH1A1
SCHEMBL18740289 0.85 MEN1 (0.44) KDM4ELMNAPKMMEN1KMT2A
SCHEMBL18740201 0.85 MEN1 (0.54) KDM4EPKMMEN1KMT2AALDH1A1
SCHEMBL28616118 0.84 PTGER4 (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434246-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-09-06 — — US disclosed
EP-3362454-B1 EP4 ANTAGONISTS EISAI R&D MAN CO LTD (JP) 2021-12-08 — — EP disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
CN-108473497-B EP4 antagonists 卫材R&D 管理有限公司 2021-09-10 — — CN disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-20180305362-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-10-25 — — US disclosed
EP-3362454-A1 EP4 ANTAGONISTS Eisai R&D Management Co., Ltd. (JP) 2018-08-22 — — EP disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434246-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 KDM4E 942/4885LMNA 3809/4885PKM 1460/4885
US-20180305362-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 KDM4E 942/4885LMNA 3809/4885PKM 1460/4885
US-10316040-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 KDM4E 942/4885LMNA 3809/4885PKM 1460/4885
US-10941148-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 KDM4E 942/4885LMNA 3809/4885PKM 1460/4885
US-20190315754-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 KDM4E 942/4885LMNA 3809/4885PKM 1460/4885
US-20210347779-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 KDM4E 942/4885LMNA 3809/4885PKM 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback